NCT03471169

Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease

Studies on the Individualized Prevention of Cerebrovascular Disease Using Study on Antithrombotic Therapy in Beijing

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 3,500 (estimated)
• Sponsor: Xuanwu Hospital, Beijing · Academic / Other
• Sex: All
• Age: 14 Years – 80 Years
• Healthy volunteers: Accepted

Summary

To investigate the therapeutic effect of individualized treatment of antiplatelet in secondary prevention of ischemic stroke.

Detailed description

Ischemic stroke is a leading cause of disability and death worldwide. Antiplatelet treatment is one of treatment strategies in secondary stroke prevention for patients with non-cardioemoblism etiology. However, a concerning issue is that wide interindividual variability in P2Y12 antagonist, especially clopidogrel. The rate on-treatment high platelet reactivity (HPR) can be as high as in one-third of patients with standard dose of clopidogrel( i.e. 75mg), and HPR has been noted in those who received other P2Y12 antagonists, such as ticagrelor and prasugrel. In the present study, we aimed to investigate the safety and potential therapeutic effect of individualized treatment of antiplatelet in secondary prevention in a cohort of patients with non-cardioembolic ischemic strokes.

Conditions

• Cerebrovascular Disease

Interventions

Type	Name	Description
DRUG	Desirable TEG	Change the type and dose of antithrombotic therapy and obtain desirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
DRUG	Undesirable TEG	Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.

Timeline

• Start date: 2017-04-01
• Primary completion: 2018-12-01
• Completion: 2018-12-01
• First posted: 2018-03-20
• Last updated: 2018-03-20

Locations

1 site across 1 country: China